These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 16104078)
21. Adverse events related to muraglitazar use in diabetes. Najman DM JAMA; 2006 May; 295(17):1997; author reply 1998. PubMed ID: 16670404 [No Abstract] [Full Text] [Related]
22. Type 2 diabetes, psoriasis and thiazolidinediones. Krentz AJ; Friedmann PS Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655 [TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451 [TBL] [Abstract][Full Text] [Related]
24. Glycemic control in youth with type 2 diabetes. Krishnan N; Krishnan R N Engl J Med; 2012 Sep; 367(11):1066; author reply 1066-7. PubMed ID: 22970956 [No Abstract] [Full Text] [Related]
25. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Consoli A; Formoso G Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285 [TBL] [Abstract][Full Text] [Related]
26. Introduction: beyond glycemic control in type 2 diabetes. Barnett AH Curr Med Res Opin; 2006; 22 Suppl 2():S1-4. PubMed ID: 16914070 [No Abstract] [Full Text] [Related]
27. The pluses of pioglitazone. Meyers L Diabetes Forecast; 2005 Sep; 58(9):39. PubMed ID: 16187433 [No Abstract] [Full Text] [Related]
28. American diabetes association - 65th Scientific Sessions. Erlich R IDrugs; 2005 Aug; 8(8):605-7. PubMed ID: 16044360 [No Abstract] [Full Text] [Related]
29. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF; Lohray BB J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
30. Pioglitazone. Kalra S; Gupta Y J Pak Med Assoc; 2015 Mar; 65(3):333-5. PubMed ID: 26554102 [No Abstract] [Full Text] [Related]
31. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks. Krumholz HM Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):221-2. PubMed ID: 20181986 [No Abstract] [Full Text] [Related]
32. Glycemic durability of monotherapy for diabetes. Garg R N Engl J Med; 2007 Mar; 356(13):1379; author reply 1380. PubMed ID: 17402165 [No Abstract] [Full Text] [Related]
33. Present recommendations in type 2 diabetes treatment. Lebovitz HE Endocrinol Nutr; 2009 Dec; 56 Suppl 4():46-9. PubMed ID: 20629232 [No Abstract] [Full Text] [Related]
34. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Hu M; Zheng C; Gao F Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440 [TBL] [Abstract][Full Text] [Related]
35. New therapeutic options: management strategies to optimize glycemic control. Sisam DA J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302 [No Abstract] [Full Text] [Related]
36. Actos and Avandia in type 2 diabetes. Where do they fit? Clark W Diabetes Self Manag; 2007; 24(4):8, 11-3. PubMed ID: 17663078 [No Abstract] [Full Text] [Related]
37. The value equation for rosiglitazone and pioglitazone in older persons. Zarowitz BJ Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172 [No Abstract] [Full Text] [Related]
39. Effectiveness and side effects of thiazolidinediones for type 2 diabetes. Arnold N; McLean M; Chipps DR; Cheung NW Med J Aust; 2005 May; 182(9):494. PubMed ID: 15999431 [No Abstract] [Full Text] [Related]
40. Rosiglitazone: a case of regulatory hubris. Nissen SE BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]